The DOI matches its Crossref record; 131 of the 134 references it cites were found in a registry or an index.
Ocular Drug Delivery: Advancements and Innovations
Open accessAbstract
Ocular drug delivery has been significantly advanced for not only pharmaceutical compounds, such as steroids, nonsteroidal anti-inflammatory drugs, immune modulators, antibiotics, and so forth, but also for the rapidly progressed gene therapy products. For conventional non-gene therapy drugs, appropriate surgical approaches and releasing systems are the main deliberation to achieve adequate treatment outcomes, whereas the scope of “drug delivery” for gene therapy drugs further expands to transgene construct optimization, vector selection, and vector engineering. The eye is the particularly well-suited organ as the gene therapy target, owing to multiple advantages. In this review, we will delve into three main aspects of ocular drug delivery for both conventional drugs and adeno-associated virus (AAV)-based gene therapy products: (1) the development of AAV vector systems for ocular gene therapy, (2) the innovative carriers of medication, and (3) administration routes progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Presently, there are more than 40 active clinical trials or follow ups for ocular diseases using AAV vectors alone.154”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [154]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040
Tham, Y.-C., Li, X., Wong, T. Y., Quigley, H. A., Aung, T., & Cheng, C.-Y. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.013 · Cited by 7,159
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952 · cited 9×
“Since the advent of the first FDA‐approved gene therapy, LuxturnaTM, for the treatment of type 2 Leber congenital amaurosis (LCA) [4], ophthalmic gene therapy research has blossomed.”
BackgroundMethodInfluentialDunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
Trial of tocilizumab in giant-cell arteritis
Stone, J. H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., Brouwer, E., Cid, M. C., Dasgupta, B., Rech, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613849 · Cited by 1,386
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362 · cited 1×
“They are small (~26 nm diameter), icosahedral-structured capsid, non-enveloped, singlestranded DNA, non-pathogenic viruses [11].”
BackgroundNanostructured lipid matrices for improved microencapsulation of drugs
Müller, R. H., Radtke, M., & Wissing, S. A. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00180-1 · Cited by 1,226
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Non Viral Vectors in Gene Therapy- An Overview
Ramamoorth, M. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10443.5394 · Cited by 761
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Research works printed but not linked: 9
- Komaromy, 2021, Four-year follow up of intraocular pressure (IOP) control in a canine model of open-angle glaucoma (OAG) treated with adeno-associated virus (AAV)-mediated modification of gene expression within the aqueous humor outflow pathways (AHOP), Investig. Ophthalmol. Vis. Sci., 62, 2783
- Visuvanathan, S. (2019). The Effects of AAV-Mediated XIAP Gene Therapy in a Mouse Model of Glaucoma. [Master’s Thesis, Université d’Ottawa/University of Ottawa].
- Bilsbury, 2022, AAV-mediated anti-VEGF therapeutics increase corneal allograft survival-rate in a model of high-risk corneal transplantation, Investig. Ophthalmol. Vis. Sci., 63, 72-A0045
- Garrigue, 2011, A Comparative Study of Latanoprost-Cationic Emulsion (Catioprost) and Latanoprost Aqueous Solution (Xalatan) in Preclinical Efficacy and Safety Models, Investig. Ophthalmol. Vis. Sci., 52, 238
- Biswas, 2017, Niosomes in ocular drug delivery, Eur. J. Pharm. Med. Res, 4, 813
- Avti, P., Patel, S., and Sitharaman, B. (2016). Nanobiomaterials Handbook, CRC Press.
- Van Ooteghem, M.M. (2019). Biopharmaceutics of Ocular Drug Delivery, CRC Press.
- Varma, 2018, Sustained release drug delivery: Closer than you think, Glaucoma Today, 3, 58
- Sedlavek, 1965, Possibilities of application of ophthalmic drugs with the aid of gel contact lens, Cesk. Oftalmol., 21, 509
Cited by
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Mucoadhesive-to-Mucopenetrating Nanoparticles for Mucosal Drug Delivery: A Mini Review
Zheng, B., Liu, D., Qin, X., Zhang, D., & Zhang, P. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s505427 · Cited by 71
“As a result, insufficient release of the mucus-penetrating ligands eventually leads to the retention of nanoparticles in the mucus layer and their removal.”
How can machine learning and multiscale modeling benefit ocular drug development?
Wang, N., Zhang, Y., Wang, W., Ye, Z., Chen, H., Hu, G., & Ouyang, D. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114772 · Cited by 58
Kannan, R. M., Pitha, I., & Parikh, K. S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115005 · Cited by 53
Chandel, A., & Kandav, G. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105785 · Cited by 49
Metadata
- Authors
- Tian, B., Bilsbury, E., Doherty, S., Teebagy, S., Wood, E., Su, W., Gao, G., & Lin, H.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Gao, Guangping
- Lin, Haijiang
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-09-13
- Volume
- 14
- Issue
- 9
- Pages
- 1931
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9506479
- OpenAlex
- W4296005586
- Cited by
- 50
- References
- 134
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 14 · 2023: 15
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- BrightFocus Foundation (M2019074)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- ocular drug delivery, ocular gene therapy, adeno-associated virus vectors, vector selection, gene therapy vectors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ocular Drug Delivery: Advancements and Innovations. https://app.cochat.ai/papers/10.3390/pharmaceutics14091931
- The paper
- Tian, B., Bilsbury, E., Doherty, S., Teebagy, S., Wood, E., Su, W., Gao, G., & Lin, H. (2022). Ocular Drug Delivery: Advancements and Innovations. Pharmaceutics. https://doi.org/10.3390/pharmaceutics14091931
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.